Format

Send to

Choose Destination
Curr Opin Microbiol. 2017 Jun;37:155-160. doi: 10.1016/j.mib.2017.08.005. Epub 2017 Sep 6.

Using CRISPR-Cas systems as antimicrobials.

Author information

1
Synthetic Biology Group, Microbiology Department, Institut Pasteur, Paris 75015, France. Electronic address: david.bikard@pasteur.fr.
2
Department of Food, Processing and Nutritional Sciences, North Carolina State University, NC, USA. Electronic address: rbarran@ncsu.edu.

Abstract

Although CRISPR-Cas systems naturally evolved to provide adaptive immunity in bacteria and archaea, Cas nucleases can be co-opted to target chromosomal sequences rather than invasive genetic elements. Although genome editing is the primary outcome of self-targeting using CRISPR-based technologies in eukaryotes, self-targeting by CRISPR is typically lethal in bacteria. Here, we discuss how DNA damage introduced by Cas nucleases in bacteria can efficiently and specifically lead to plasmid curing or drive cell death. Specifically, we discuss how various CRISPR-Cas systems can be engineered and delivered using phages or phagemids as vectors. These principles establish CRISPR-Cas systems as potent and programmable antimicrobials, and open new avenues for the development of CRISPR-based tools for selective removal of bacterial pathogens and precise microbiome composition alteration.

PMID:
28888103
DOI:
10.1016/j.mib.2017.08.005
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science Icon for HAL archives ouvertes
Loading ...
Support Center